Phase 2 trial shows daridorexant boosts pediatric insomnia sleep time up to 50 minutes, including ADHD/ASD patients, with strong safety and phase 3 plans.
|Slideshows|April 17, 2020
Team Earth: A Message of Hope
Author(s)H. Steven Moffic, MD
"Mom says viruses don’t attack countries, they attack people. And across countries we are still one people living under one roof." More in this pictorial and therapeutic dialog between a 5-year-old and his mother about the pandemic.
Advertisement
Advertisement
Related to this article
Phase 2 trial finds bezisterim shows safety and symptom gains in long COVID, with strongest benefits for severe fatigue, PEM, and cognitive issues.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Food Noise and GLP-1 Drugs: What Research Reveals About Motivation and Appetitive Drive
2
GLP-1 Receptor Agonists May Reinforce Restriction in Patients With Eating Disorders
3
Psychedelic Trials Reveal Gaps Between Controlled Efficacy and Real-World Readiness
4
Dementia Pipeline Update: Phase 2 and 3 Developments in Alzheimer Disease and Lewy Body Dementia
5